Shopping Cart 0
Cart Subtotal
USD 0

United Kingdom Metered Dose Inhaler Devices Market Outlook to 2023

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 4995

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 9990

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 14985
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

United Kingdom Metered Dose Inhaler Devices Market Outlook to 2023

Summary

GlobalData's new report, "United Kingdom Metered Dose Inhaler Devices Market Outlook to 2023", provides key market data on the United Kingdom Metered Dose Inhaler Devices market. The report provides value, in millions of US dollars, volume (in units) and and average prices (USD) for Metered Dose Inhaler Devices.

The report also provides company shares and distribution shares data for each of these market segments, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope

Market size and company share data for Metered Dose Inhaler Devices.

Annualized market revenues (USD million) and volume (units) data for each of the market segments. Data is provided from 2009 to 2016 and forecast to 2023.

2016 company shares and distribution shares data for each of the market segments.

Global corporate-level profiles of key companies operating within the United Kingdom Metered Dose Inhaler Devices market.

Key players covered include GlaxoSmithKline Plc, AstraZeneca Plc and Boehringer Ingelheim GmbH.

Reasons to buy

Develop business strategies by identifying the key market segments poised for strong growth in the future.

Develop market-entry and market expansion strategies.

Design competition strategies by identifying who-stands-where in the market.

Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.

What are the key distribution channels and what's the most preferred mode of product distribution-Identify, understand and capitalize.

READ MORE

Table Of Content

Scope

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 4

1.2 List of Figures 4

2 Introduction 5

2.1 What Is This Report About? 5

2.2 Metered Dose Inhaler Devices Market Segmentation 5

2.3 Definitions of Markets Covered in the Report 5

3 Metered Dose Inhaler Devices Market, United Kingdom 6

3.1 Metered Dose Inhaler Devices Market, United Kingdom, Revenue ($m), 2009-2016 6

3.2 Metered Dose Inhaler Devices Market, United Kingdom, Revenue ($m), 2016-2023 8

3.3 Metered Dose Inhaler Devices Market, United Kingdom, Volume (Units), 2009-2016 9

3.4 Metered Dose Inhaler Devices Market, United Kingdom, Volume (Units), 2016-2023 10

3.5 Metered Dose Inhaler Devices Market, United Kingdom, Average Price ($), 2009-2023 11

3.6 Metered Dose Inhaler Devices Market, United Kingdom, Distribution Share by Revenue ($m), 2015-2016 12

3.7 Metered Dose Inhaler Devices Market, United Kingdom, Company Share by Revenue ($m), 2016 13

4 Overview of Key Companies in United Kingdom, Metered Dose Inhaler Devices Market 15

4.1 GlaxoSmithKline Plc 15

4.1.1 Company Overview 15

4.2 AstraZeneca Plc 15

4.2.1 Company Overview 15

4.3 Boehringer Ingelheim GmbH 15

4.3.1 Company Overview 15

4.4 Pfizer Inc 16

4.4.1 Company Overview 16

4.5 Merck & Co Inc 16

4.5.1 Company Overview 16

5 Financial Deals Landscape 17

5.1 Debt Offerings 17

5.1.1 Mylan Raises USD551.6 Million in Public Offering of Bonds Due 2020 17

6 Recent Developments 18

6.1 Corporate Communications 18

6.1.1 May 01, 2017: Mylan Nominates Sjoerd Vollebregt for Election to Board of Directors 18

6.1.2 Mar 28, 2017: Mylan Names Former SEC Commissioner Daniel Gallagher as Chief Legal Officer 18

6.1.3 Mar 22, 2017: BioStable Science & Engineering Announces FDA Clearance of the HAART 300 Aortic Annuloplasty Device 19

6.1.4 Mar 06, 2017: Vectura Group: Board Change 20

6.1.5 Dec 14, 2016: Consort Medical: Directorate Change 20

6.1.6 Nov 25, 2016: Consort Medical: CFO Appointment 21

6.1.7 Aug 17, 2016: Consort Medical Announces Directorate Change 21

6.1.8 Jul 08, 2016: Dr John Brown, Non-Executive Director, confirms date to step down 21

6.2 Financial Announcements 22

6.2.1 Jun 15, 2017: Consort Medical: Full year results 22

6.2.2 May 31, 2017: Lamellar Biomedical Recruits First Patients into Clinical Study Assessing LAMELLEYE for Treatment of Dry Eye Disease 22

6.2.3 May 10, 2017: Mylan Reports First Quarter 2017 Results 24

6.2.4 Apr 05, 2017: InVivo Therapeutics Announces New Patient Enrollment into the INSPIRE Study at the Carolinas Medical Center 26

6.2.5 Mar 29, 2017: Peer-Reviewed Clinical Study Shows ID Genomics' Bacterial Fingerprinting Technology Can Reduce Prescription Errors and Antibiotic Overuse at the Point-of-Care 26

6.2.6 Mar 21, 2017: Vectura Group: Preliminary Results for the nine-month period ended 31 December 2016 29

6.2.7 Mar 21, 2017: Vectura Group Announces Preliminary Results for the nine-month period ended 31 December 2016 30

6.2.8 Mar 01, 2017: Mylan Reports Fourth Quarter and Full Year 2016 Results and Provides 2017 Guidance 31

6.2.9 Dec 06, 2016: Consort Medical Reports Interim Results Results For The Six Months Ended 31 October 2016 33

6.2.10 Nov 09, 2016: Mylan Reports Third Quarter 2016 Results 34

6.2.11 Aug 09, 2016: Mylan Reports Strong Second Quarter 2016 Results Including Total Revenues Up 8% 38

6.3 Other Significant Developments 41

6.3.1 Feb 16, 2017: Vectura achieves 9 million royalty cap from GSK Ellipta products 41

6.3.2 Jan 11, 2017: Vectura Group: Pre-close update 41

6.3.3 Sep 07, 2016: New Scale-Up and Commercial Supply Agreement 42

7 Appendix 44

7.1 Research Methodology 45

7.1.1 Coverage 45

7.1.2 Secondary Research 45

7.1.3 Primary Research 46

7.1.4 Company Share Analysis 46

7.1.5 Distribution Share Analysis 46

7.1.6 Benchmarking 47

7.2 GlobalData Consulting 47

7.3 Contact Us 48

7.4 Disclaimer 48


List Of Figure

1.2 List of Figures

Figure 1: Metered Dose Inhaler Devices Market, United Kingdom, Revenue ($m), USD Constant, Historic, 2009-2016 6

Figure 2: Metered Dose Inhaler Devices Market, United Kingdom, Revenue ($m), USD Constant, Forecast, 2016-2023 8

Figure 3: Metered Dose Inhaler Devices Market, United Kingdom, Volume (Units), Historic, 2009-2016 9

Figure 4: Metered Dose Inhaler Devices Market, United Kingdom, Volume (Units), Forecast, 2016-2023 10

Figure 5: Metered Dose Inhaler Devices Market, United Kingdom, Company Share (%) 2016 13


List Of Table

1.1 List of Tables

Table 1: Metered Dose Inhaler Devices Market, United Kingdom, Revenue ($m), USD Constant, Historic, 2009-2016 6

Table 2: Metered Dose Inhaler Devices Market, United Kingdom, Revenue ($m), USD Constant, Forecast, 2016-2023 8

Table 3: Metered Dose Inhaler Devices Market, United Kingdom, Volume (Units), Historic, 2009-2016 9

Table 4: Metered Dose Inhaler Devices Market, United Kingdom, Volume (Units), Forecast, 2016-2023 10

Table 5: Metered Dose Inhaler Devices Market, United Kingdom, Average Price ($), Historic, 2009-2016 11

Table 6: Metered Dose Inhaler Devices Market, United Kingdom, Average Price ($), Forecast, 2016-2023 11

Table 7: Metered Dose Inhaler Devices Market, United Kingdom, Distribution Share by Revenue ($m), USD Constant, 2015-2016 12

Table 8: Metered Dose Inhaler Devices Market, United Kingdom, Company Share by Revenue ($m), USD Constant, 2016 14

Table 9: Mylan Raises USD551.6 Million in Public Offering of Bonds Due 2020 17

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Drug Delivery Devices, Central Venous Catheters, Needle Free Injections, Infusion Systems, Metered Dose Inhaler Devices, Value (USD), Volume (units), Revenues, Historic Revenues, Forecast Revenues, Average Price, Company Share, Distribution Share by Revenue, Company Share by Revenue, Pipeline Products, News, Deals, Key Companies, GlaxoSmithKline Plc, AstraZeneca Plc, Boehringer Ingelheim GmbH, Pfizer Inc, Merck & Co Inc, Sunovion Pharmaceuticals Inc, Teva Pharmaceutical Industries Ltd, INJEX-Equidyne Systems, Bioject Medical Technologies Inc , Antares Pharma Inc, PharmaJet Inc, MK Global Co., The European Pharma Group, Hospira Inc, Becton Dickinson and Co, Baxter International Inc, Fresenius Kabi AG, Medtronic plc, B. Braun Melsungen AG, Terumo Corp, Smiths Medical, Nipro Corp, JMS Co Ltd


Companies

GlaxoSmithKline Plc

AstraZeneca Plc

Boehringer Ingelheim GmbH

Pfizer Inc

Merck & Co Inc

United Kingdom Metered Dose Inhaler Devices Market Outlook to 2023

Summary

GlobalData's new report, "United Kingdom Metered Dose Inhaler Devices Market Outlook to 2023", provides key market data on the United Kingdom Metered Dose Inhaler Devices market. The report provides value, in millions of US dollars, volume (in units) and and average prices (USD) for Metered Dose Inhaler Devices.

The report also provides company shares and distribution shares data for each of these market segments, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope

Market size and company share data for Metered Dose Inhaler Devices.

Annualized market revenues (USD million) and volume (units) data for each of the market segments. Data is provided from 2009 to 2016 and forecast to 2023.

2016 company shares and distribution shares data for each of the market segments.

Global corporate-level profiles of key companies operating within the United Kingdom Metered Dose Inhaler Devices market.

Key players covered include GlaxoSmithKline Plc, AstraZeneca Plc and Boehringer Ingelheim GmbH.

Reasons to buy

Develop business strategies by identifying the key market segments poised for strong growth in the future.

Develop market-entry and market expansion strategies.

Design competition strategies by identifying who-stands-where in the market.

Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.

What are the key distribution channels and what's the most preferred mode of product distribution-Identify, understand and capitalize.

READ MORE

Scope

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 4

1.2 List of Figures 4

2 Introduction 5

2.1 What Is This Report About? 5

2.2 Metered Dose Inhaler Devices Market Segmentation 5

2.3 Definitions of Markets Covered in the Report 5

3 Metered Dose Inhaler Devices Market, United Kingdom 6

3.1 Metered Dose Inhaler Devices Market, United Kingdom, Revenue ($m), 2009-2016 6

3.2 Metered Dose Inhaler Devices Market, United Kingdom, Revenue ($m), 2016-2023 8

3.3 Metered Dose Inhaler Devices Market, United Kingdom, Volume (Units), 2009-2016 9

3.4 Metered Dose Inhaler Devices Market, United Kingdom, Volume (Units), 2016-2023 10

3.5 Metered Dose Inhaler Devices Market, United Kingdom, Average Price ($), 2009-2023 11

3.6 Metered Dose Inhaler Devices Market, United Kingdom, Distribution Share by Revenue ($m), 2015-2016 12

3.7 Metered Dose Inhaler Devices Market, United Kingdom, Company Share by Revenue ($m), 2016 13

4 Overview of Key Companies in United Kingdom, Metered Dose Inhaler Devices Market 15

4.1 GlaxoSmithKline Plc 15

4.1.1 Company Overview 15

4.2 AstraZeneca Plc 15

4.2.1 Company Overview 15

4.3 Boehringer Ingelheim GmbH 15

4.3.1 Company Overview 15

4.4 Pfizer Inc 16

4.4.1 Company Overview 16

4.5 Merck & Co Inc 16

4.5.1 Company Overview 16

5 Financial Deals Landscape 17

5.1 Debt Offerings 17

5.1.1 Mylan Raises USD551.6 Million in Public Offering of Bonds Due 2020 17

6 Recent Developments 18

6.1 Corporate Communications 18

6.1.1 May 01, 2017: Mylan Nominates Sjoerd Vollebregt for Election to Board of Directors 18

6.1.2 Mar 28, 2017: Mylan Names Former SEC Commissioner Daniel Gallagher as Chief Legal Officer 18

6.1.3 Mar 22, 2017: BioStable Science & Engineering Announces FDA Clearance of the HAART 300 Aortic Annuloplasty Device 19

6.1.4 Mar 06, 2017: Vectura Group: Board Change 20

6.1.5 Dec 14, 2016: Consort Medical: Directorate Change 20

6.1.6 Nov 25, 2016: Consort Medical: CFO Appointment 21

6.1.7 Aug 17, 2016: Consort Medical Announces Directorate Change 21

6.1.8 Jul 08, 2016: Dr John Brown, Non-Executive Director, confirms date to step down 21

6.2 Financial Announcements 22

6.2.1 Jun 15, 2017: Consort Medical: Full year results 22

6.2.2 May 31, 2017: Lamellar Biomedical Recruits First Patients into Clinical Study Assessing LAMELLEYE for Treatment of Dry Eye Disease 22

6.2.3 May 10, 2017: Mylan Reports First Quarter 2017 Results 24

6.2.4 Apr 05, 2017: InVivo Therapeutics Announces New Patient Enrollment into the INSPIRE Study at the Carolinas Medical Center 26

6.2.5 Mar 29, 2017: Peer-Reviewed Clinical Study Shows ID Genomics' Bacterial Fingerprinting Technology Can Reduce Prescription Errors and Antibiotic Overuse at the Point-of-Care 26

6.2.6 Mar 21, 2017: Vectura Group: Preliminary Results for the nine-month period ended 31 December 2016 29

6.2.7 Mar 21, 2017: Vectura Group Announces Preliminary Results for the nine-month period ended 31 December 2016 30

6.2.8 Mar 01, 2017: Mylan Reports Fourth Quarter and Full Year 2016 Results and Provides 2017 Guidance 31

6.2.9 Dec 06, 2016: Consort Medical Reports Interim Results Results For The Six Months Ended 31 October 2016 33

6.2.10 Nov 09, 2016: Mylan Reports Third Quarter 2016 Results 34

6.2.11 Aug 09, 2016: Mylan Reports Strong Second Quarter 2016 Results Including Total Revenues Up 8% 38

6.3 Other Significant Developments 41

6.3.1 Feb 16, 2017: Vectura achieves 9 million royalty cap from GSK Ellipta products 41

6.3.2 Jan 11, 2017: Vectura Group: Pre-close update 41

6.3.3 Sep 07, 2016: New Scale-Up and Commercial Supply Agreement 42

7 Appendix 44

7.1 Research Methodology 45

7.1.1 Coverage 45

7.1.2 Secondary Research 45

7.1.3 Primary Research 46

7.1.4 Company Share Analysis 46

7.1.5 Distribution Share Analysis 46

7.1.6 Benchmarking 47

7.2 GlobalData Consulting 47

7.3 Contact Us 48

7.4 Disclaimer 48


List Of Figure

1.2 List of Figures

Figure 1: Metered Dose Inhaler Devices Market, United Kingdom, Revenue ($m), USD Constant, Historic, 2009-2016 6

Figure 2: Metered Dose Inhaler Devices Market, United Kingdom, Revenue ($m), USD Constant, Forecast, 2016-2023 8

Figure 3: Metered Dose Inhaler Devices Market, United Kingdom, Volume (Units), Historic, 2009-2016 9

Figure 4: Metered Dose Inhaler Devices Market, United Kingdom, Volume (Units), Forecast, 2016-2023 10

Figure 5: Metered Dose Inhaler Devices Market, United Kingdom, Company Share (%) 2016 13


List Of Table

1.1 List of Tables

Table 1: Metered Dose Inhaler Devices Market, United Kingdom, Revenue ($m), USD Constant, Historic, 2009-2016 6

Table 2: Metered Dose Inhaler Devices Market, United Kingdom, Revenue ($m), USD Constant, Forecast, 2016-2023 8

Table 3: Metered Dose Inhaler Devices Market, United Kingdom, Volume (Units), Historic, 2009-2016 9

Table 4: Metered Dose Inhaler Devices Market, United Kingdom, Volume (Units), Forecast, 2016-2023 10

Table 5: Metered Dose Inhaler Devices Market, United Kingdom, Average Price ($), Historic, 2009-2016 11

Table 6: Metered Dose Inhaler Devices Market, United Kingdom, Average Price ($), Forecast, 2016-2023 11

Table 7: Metered Dose Inhaler Devices Market, United Kingdom, Distribution Share by Revenue ($m), USD Constant, 2015-2016 12

Table 8: Metered Dose Inhaler Devices Market, United Kingdom, Company Share by Revenue ($m), USD Constant, 2016 14

Table 9: Mylan Raises USD551.6 Million in Public Offering of Bonds Due 2020 17

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Drug Delivery Devices, Central Venous Catheters, Needle Free Injections, Infusion Systems, Metered Dose Inhaler Devices, Value (USD), Volume (units), Revenues, Historic Revenues, Forecast Revenues, Average Price, Company Share, Distribution Share by Revenue, Company Share by Revenue, Pipeline Products, News, Deals, Key Companies, GlaxoSmithKline Plc, AstraZeneca Plc, Boehringer Ingelheim GmbH, Pfizer Inc, Merck & Co Inc, Sunovion Pharmaceuticals Inc, Teva Pharmaceutical Industries Ltd, INJEX-Equidyne Systems, Bioject Medical Technologies Inc , Antares Pharma Inc, PharmaJet Inc, MK Global Co., The European Pharma Group, Hospira Inc, Becton Dickinson and Co, Baxter International Inc, Fresenius Kabi AG, Medtronic plc, B. Braun Melsungen AG, Terumo Corp, Smiths Medical, Nipro Corp, JMS Co Ltd


Companies

GlaxoSmithKline Plc

AstraZeneca Plc

Boehringer Ingelheim GmbH

Pfizer Inc

Merck & Co Inc

chat_bubbleLet's Chat